Results 111 to 120 of about 410,734 (218)

Dasatinib and Pulmonary Arterial Hypertension: When Cardio-Oncology Meets the Pulmonary Circulation. [PDF]

JACC Case Rep
Sreedhara K, Ghawanmeh M, Gomberg-Maitland M.   +2 more
europepmc   +1 more source

Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis–associated pulmonary arterial hypertension: a EUSTAR analysis

Arthritis &Rheumatology, Accepted Article.
Objective Real‐world initial treatment strategies in SSc‐PAH remain incompletely described. We aimed to characterise these strategies across haemodynamic thresholds and risk strata and evaluate outcome associations. Methods We analysed treatment‐naïve SSc‐PAH patients in EUSTAR (2000–2021) fulfilling the 2022 haemodynamic definition.
Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, Cathrine Brunborg, Patricia E Carreira, Paolo Airò, Carmen Pilar Simeón‐Aznar, Marie‐Elise Truchetet, Alessandro Giollo, Alexandra Balbir‐Gurman, Mickael Martin, Christopher P Denton, Armando Gabrielli, Francesco Del Galdo, Madelon C. Vonk, Håvard Fretheim, Helle Bitter, Øyvind Midtvedt, Arne K. Andreassen, Sverre Høie, Yoshiya Tanaka, Gabriela Riemekasten, Ulf Müller‐Ladner, Marco Matucci‐Cerinic, Ivan Castellví, Elise Siegert, Eric Hachulla, Øyvind Molberg, Oliver Distler, Anna‐Maria Hoffmann‐Vold, on behalf of the EUSTAR collaborators   +30 more
wiley   +1 more source

Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis

Arthritis &Rheumatology, Accepted Article.
Objective We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro. Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=
Jaime Marty, Sara Martinez‐Ramos, Carlos Rafael‐Vidal, Beatriz Malvar‐Fernández, Tiago Carvalheiro, Ralph G. Tieland, Ines Ramos, Wiola Marut, Ana Pinheiro‐Lopes, Ana Argibay, Brenda Maure, Caritina Vázquez‐Triñanes, Nair Pérez Gómez, David Fernández‐Fernández, Sandra Vila, Coral Mouriño, Rogier M Thurlings, Arjan van Caam, Alberto Rivera, José María Pego‐Reigosa, Timothy R. Radstake, Samuel Garcia   +21 more
wiley   +1 more source

Sorting Out Vasoreactivity in Pulmonary Arterial Hypertension With SNX29. [PDF]

Circ Res
Creager MD, Yu PB.
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Outcomes in Pulmonary Arterial Hypertension: Results from a Single Center in Romania. [PDF]

J Clin Med
Neagu A, Leu Ș, Zaharia DC, Toma CL, Enache R, Perpelea DV, Predescu L, Platon P, Bogdan MA, Constantinescu T.   +9 more
europepmc   +1 more source

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

British Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang, Ana Soldo, Olgica Velkovski Škopić, Sunčana Vlah Tomičević, Tin Šaban, Andrej Belančić, Ana Jelaković, Josipa Josipović, Mihaela Marinović Glavić, Ivan Pećin, Luka Prgomet, Tajana Željković Vrkić, Bojan Jelaković   +12 more
wiley   +1 more source

Severe Pulmonary Arterial Hypertension in Pregnancy: Multidisciplinary Management and Avoidance of Oxytocin. [PDF]

JACC Case Rep
Ahn KJ, Chung WJ, Jang AY, Choi CH, Lee KC, Kim SY.   +5 more
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source